Xuan, G. S. published the artcileInhibition of carbonic anhydrase II by sulfonamide derivatives, SDS of cas: 56-05-3, the publication is Pharmazie (2021), 76(9), 412-415, database is CAplus and MEDLINE.
A series of sulfonamide derivatives I [R = NH2, ethoxycarbonylazanyl, (pyrimidin-2-yl)aminyl, 3-methyl-5-phenyl-1H-pyrazol-1-yl, etc.; R1 = H, C(O)CH3] were synthesized, and the enzyme inhibitory activity of the synthesized compounds I on carbonic anhydrase II was evaluated. Through mol. docking studies, it was found that compounds I [R = NHNH2, R1 = C(O)CH3; R = (pyrimidin-2-yl)aminyl, R1 = C(O)CH3 (II); R = acetamidyl, R1 = C(O)CH3; R = ethoxycarbonylazanyl, R1 = C(O)CH3 (III); R = 3,5-dimethyl-1H-pyrazol-1-yl, R1 = H (IV)] have a strong binding affinity to carbonic anhydrase II. The IC50 values of the four compounds II, III, IV and I (R = 3-methyl-5-phenyl-1H-pyrazol-1-yl; R1 = H) were lower than that of the pos. control drug acetazolamide. What’s more, the compounds had a high inhibitory activity for A549 lung cancer cell growth, among them, II and IV could inhibit both carbonic anhydrase II and lung cancer cell proliferation.
Pharmazie published new progress about 56-05-3. 56-05-3 belongs to pyrimidines, auxiliary class Pyrimidine,Chloride,Amine,API, name is 2-Amino-4,6-dichloropyrimidine, and the molecular formula is C24H12, SDS of cas: 56-05-3.
Referemce:
https://pubchem.ncbi.nlm.nih.gov/compound/Pyrimidine,
Pyrimidine – Wikipedia